A comparison of overall survival with 40 and 50 mg/m 2 pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: Propensity score-matched analysis of real-world data-Reference-Cited by-同舟云学术

A comparison of overall survival with 40 and 50 mg/m 2 pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: Propensity score-matched analysis of real-world data

Published:2016-11 Issue:2 Volume:143 Page:246-251
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Nakayama Masahiko^ORCID,Kobayashi Hisanori,Takahara Tomihiro,Nishimura Yukiko,Fukushima Koji,Yoshizawa Kazutake

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference40 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int. J. Cancer,2015

2. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study;Ozols;J. Clin. Oncol.,2003

3. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Ledermann;Ann. Oncol.,2013

4. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies;Uziely;J. Clin. Oncol.,1995

5. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer;Gordon;J. Clin. Oncol.,2000

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of formulation parameters and circulation time on PEGylated liposomal doxorubicin related hand-foot syndrome;International Journal of Pharmaceutics;2024-11

2. Efficacy of regional cooling + oral dexamethasone for primary prevention of hand-foot syndrome associated with pegylated liposomal doxorubicin;Supportive Care in Cancer;2023-04-19

3. Prevalence of acute oral mucosal damage secondary to the use of systemic antineoplastics: A systematic review and meta-analysis;Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology;2023-03

4. How to conduct integrated pharmaceutical care for patients with hand-foot syndrome associated with chemotherapeutic agents and targeted drugs;Journal of Oncology Pharmacy Practice;2021-04-19

5. Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m2 versus 40 mg/m2 in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial;Journal of Gynecologic Oncology;2021